Pearl Street Venture Funds
Pearl Street Venture Funds is a venture capital firm founded in 2003 and headquartered in Indianapolis, Indiana. The firm specializes in early-stage investments, particularly in the life sciences sector, focusing on biotechnology, pharmaceuticals, medical devices, and agri-bio. It actively seeks opportunities in therapeutic product companies that are developing advanced technologies. Pearl Street Venture Funds has a specific interest in supporting companies based in Indiana and is capable of acting as both a lead and co-investor. While it is currently fully invested and not making new investments, its commitment to delivering superior financial returns for its limited partners remains a core objective. The firm also maintains additional offices in Los Angeles, West Lafayette, San Diego, and Gaithersburg.
Top Stages
7 past transactions
Toggle
Pre Seed Round in 2018
Toggle is a United States-based company that specializes in robotics as a service (RaaS) for the construction industry. It focuses on automating the assembly of rebar cages for reinforced concrete applications, enhancing efficiency and precision in construction processes. Toggle's offerings include two-arm robotic platforms and proprietary jig designs capable of constructing various shapes directly from computer blueprints. In addition to its core services, the company also provides pre-assembly solutions, contributing to the advancement of robotics and automation in the construction sector.
CoLucid Pharmaceuticals
Series C in 2015
CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.
CoLucid Pharmaceuticals
Venture Round in 2011
CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.
CoLucid Pharmaceuticals
Series B in 2008
CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.
Serenex
Series D in 2007
Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.
BioVigilant Systems
Series A in 2006
BioVigilant Systems specializes in advanced microbial detection technology aimed at enhancing environmental monitoring across various sectors, including pharmaceuticals, biotechnology, healthcare, and environmental applications. The company's innovative instantaneous microbial detection (IMD) systems provide real-time analysis of particulate count, size, and biological status without the need for staining, reagents, or extended waiting periods. This optically-based technology streamlines the monitoring process, minimizing human intervention and improving efficiency in critical environments.
CoLucid Pharmaceuticals
Series A in 2006
CoLucid Pharmaceuticals, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. The company focuses on innovative treatments for migraine headaches and other neurological conditions. It is advancing COL-144, a neurally acting anti-migraine agent aimed at effectively treating migraines. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform that generates new chemical entities for addressing a range of conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Established in 2005, CoLucid Pharmaceuticals is headquartered in Research Triangle Park, North Carolina.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.